Beyond First-Generation KRAS Inhibitors: BBO-8520 Tests the Dual Mechanism Hypothesis
Zhiwei Zhou1,2, Kenneth D Westover1,2
1Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
Abstract:
This issue highlights the development of a first-in-class small-molecule covalent KRASG12C inhibitor, BBO-8520, which targets both the active (ON) and inactive (OFF) states of KRAS. This dual-state targeting offers a significant opportunity to overcome the resistance mechanisms that have limited the efficacy of first-generation KRAS inhibitors and addresses critical challenges in KRAS-targeted therapy. See related article by Maciag et al., p. 578.
Insights
A novel covalent KRASG12C inhibitor, BBO-8520, targets both active and inactive states of KRAS. This dual-state approach aims to overcome resistance and improve KRAS-targeted cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- KRAS mutations are common drivers in various cancers.
- First-generation KRAS inhibitors targeting specific states face resistance.
- Developing inhibitors effective against multiple KRAS states is crucial.
Purpose of the Study:
- To introduce BBO-8520, a novel small-molecule covalent inhibitor of KRASG12C.
- To evaluate its dual-state targeting capability (active ON and inactive OFF states).
- To explore its potential in overcoming resistance mechanisms in KRAS-targeted therapy.
Main Methods:
- Development of a first-in-class small-molecule inhibitor.
- Biochemical and cellular assays to assess KRAS state binding.
- Studies on resistance mechanisms relevant to KRAS inhibitors.
Main Results:
- BBO-8520 demonstrates dual-state targeting of KRASG12C.
- This inhibitor shows potential to overcome resistance pathways.
- It represents a significant advancement in KRAS-targeted drug development.
Conclusions:
- BBO-8520 offers a promising strategy for KRAS-targeted cancer treatment.
- Dual-state inhibition may circumvent acquired resistance.
- Further clinical investigation of BBO-8520 is warranted.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...